Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Real-World Utilization of Tissue-Free ctDNA MRD Testing in Non-Small Cell Lung Cancer Across Asia-Pacific and the Middle East: A Descriptive Cohort Analysis and Illustrative Case Series

This descriptive cohort reports tissue-free (plasma-only) MRD testing in 159 patients with NSCLC (257 samples) treated in Asia-Pacific and the Middle East. First-test positivity was 15.7% (25 of 159; 95% CI 10.9-22.2). The paper does not estimate assay performance. Six purposively selected cases are presented to illustrate how results were interpreted alongside imaging; the authors describe the findings as hypothesis-generating. The abstract does not name a commercial assay.

CancersPubMed 42938831DOI 10.3390/cancers18203296